Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN

Rafferty Asset Management LLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 93.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 213,211 shares of the company’s stock after acquiring an additional 102,963 shares during the quarter. Rafferty Asset Management LLC owned about 0.15% of Dyne Therapeutics worth $2,697,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in DYN. Aberdeen Group plc grew its stake in Dyne Therapeutics by 15.0% in the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after purchasing an additional 72,770 shares during the last quarter. Saturn V Capital Management LP bought a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at about $13,856,000. Arcadia Investment Management Corp MI grew its position in shares of Dyne Therapeutics by 23.1% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock worth $526,000 after buying an additional 10,350 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Dyne Therapeutics by 334.3% in the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock worth $1,730,000 after buying an additional 139,896 shares during the last quarter. Finally, Bryce Point Capital LLC bought a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $115,000. 96.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on DYN shares. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, January 21st. Morgan Stanley dropped their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 target price on shares of Dyne Therapeutics in a research report on Monday, December 8th. Finally, Evercore lowered their price target on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $37.00.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $15.23 on Thursday. The stock has a 50-day moving average of $17.26 and a two-hundred day moving average of $17.04. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.47 and a current ratio of 22.25. The stock has a market cap of $2.51 billion, a P/E ratio of -4.30 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.